IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 3333 01
E-Mail: investor@medigene.com
pta20200928034
Business news for the stock market

Medigene AG: Medigene participates at upcoming virtual conferences


Martinsried/ Munich (pta034/28.09.2020/22:00) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that all mentioned conferences will be conducted virtually due to COVID-19.

Cell Therapy Manufacturing & Gene Therapy Congress
Date: 19 - 22 October
Website: https://informaconnect.com/celltherapy/

TCR Therapies Summit
Date: 26 - 29 October
Website: https://tcr-therapies-summit.com/

BIO-Europe Digital
Date: 26 - 29 October
Website: https://informaconnect.com/bioeurope/?gclid=EAIaIQobChMIn-75yv7b6wIVFed3Ch27uAezEAAYASAAEgLuufD_BwE

Neoantigen Based Therapies Summit
Date: 3 - 5 November
Website: https://neo-antigen.com/

35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020)
Date: 9 - 14 November
Website: https://www.sitcancer.org/events/event-description?CalendarEventKey=bcb54b5c-c612-4e28-854f-0f8c41bca69f&Home=%2Fevents%2Fevent-description

62nd ASH Annual Meeting and Exposition
Date: 5 - 8 December
Website: https://www.hematology.org/meetings/annual-meeting

- end of announcement -

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Dr Gary Waanders, Dr Anna Niedl
Tel.: +49 89 2000 3333 01
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg/Martinsried
Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: investor@medigene.com
website: www.medigene.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
|
|
97.950 Abonnenten
|
184.330 Meldungen
|
75.482 Pressefotos
Top